See more : Xi’an Typical Industries Co.,Ltd (600302.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Panacea Biotec Limited (PANACEABIO.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panacea Biotec Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Chimeric Therapeutics Limited (CHMMF) Income Statement Analysis – Financial Results
- Great Elm Capital Group, Inc. (GECCL) Income Statement Analysis – Financial Results
- Edel SE & Co. KGaA (EDL.DE) Income Statement Analysis – Financial Results
- Nicola Mining Inc. (HUSIF) Income Statement Analysis – Financial Results
- AVEVA Group plc (AVV.L) Income Statement Analysis – Financial Results
Panacea Biotec Limited (PANACEABIO.BO)
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, and gastro-intestinal care; and pneumococcal vaccine, dengue tetravalent vaccine, typhoid conjugate vaccine, and universal flu vaccine. It also exports its products to approximately 36 countries, including the United States, Germany, Russian Federation, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, Philippines, Sri Lanka, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. The company was incorporated in 1984 and is based in New Delhi, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.52B | 4.57B | 6.59B | 6.18B | 5.37B | 4.52B | 5.86B | 5.36B | 6.53B | 6.87B | 5.10B | 6.08B | 7.10B | 11.68B | 9.01B | 7.88B | 8.41B | 8.42B | 5.42B | 3.28B |
| Cost of Revenue | 2.69B | 2.79B | 3.00B | 2.29B | 1.75B | 2.03B | 2.10B | 1.71B | 2.16B | 2.80B | 2.28B | 2.63B | 3.48B | 5.86B | 4.72B | -452.62M | -4.59M | 123.48M | 12.96M | -346.95M |
| Gross Profit | 2.83B | 1.78B | 3.59B | 3.89B | 3.63B | 2.50B | 3.76B | 3.65B | 4.37B | 4.07B | 2.82B | 3.45B | 3.63B | 5.82B | 4.29B | 8.33B | 8.42B | 8.30B | 5.41B | 3.63B |
| Gross Profit Ratio | 51.27% | 38.99% | 54.49% | 63.00% | 67.50% | 55.19% | 64.10% | 68.07% | 66.96% | 59.22% | 55.22% | 56.71% | 51.05% | 49.79% | 47.61% | 105.74% | 100.05% | 98.53% | 99.76% | 110.58% |
| Research & Development | 0.00 | 139.13M | 105.09M | 125.62M | 205.13M | 157.73M | 144.60M | 425.23M | 452.80M | 83.20M | 86.20M | 84.00M | 0.00 | 753.10M | 753.20M | 669.94M | 541.86M | 505.01M | 280.93M | 140.56M |
| General & Administrative | 295.26M | 158.40M | 276.71M | 274.67M | 192.68M | 239.76M | 206.89M | 216.64M | 254.50M | 277.50M | 298.50M | 420.70M | 884.70M | 844.50M | 0.00 | 0.00 | 0.00 | 4.29B | 3.19B | 2.27B |
| Selling & Marketing | 285.24M | 231.40M | 276.68M | 228.08M | 262.60M | 198.16M | 250.85M | 284.81M | 350.80M | 330.90M | 460.90M | 488.70M | 576.50M | 481.50M | 474.70M | 458.23M | 482.79M | 342.40M | 251.15M | 203.91M |
| SG&A | 580.50M | 389.80M | 553.39M | 502.75M | 455.28M | 437.92M | 457.74M | 501.45M | 605.30M | 608.40M | 2.66B | 2.74B | 1.46B | 1.33B | 474.70M | 458.23M | 482.79M | 342.40M | 3.45B | 2.47B |
| Other Expenses | 2.25B | 33.43M | 33.97M | 20.16M | 8.66M | 20.85M | 4.88M | 144.12M | 84.20M | 24.90M | 53.80M | 0.00 | -2.90M | -3.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.83B | 2.84B | 4.11B | 3.52B | 3.21B | 3.62B | 3.35B | 3.31B | 3.81B | 3.79B | 4.33B | 5.15B | 5.18B | 3.80B | 2.73B | 8.85B | 6.39B | 6.01B | 4.28B | 3.09B |
| Cost & Expenses | 5.52B | 5.63B | 7.11B | 5.81B | 4.95B | 5.64B | 5.45B | 5.02B | 5.97B | 6.59B | 6.61B | 7.79B | 8.66B | 9.66B | 7.45B | 8.40B | 6.39B | 6.13B | 4.29B | 2.74B |
| Interest Income | 83.72M | 115.61M | 33.94M | 32.68M | 47.88M | 6.78M | 8.28M | 31.49M | 13.00M | 22.30M | 73.50M | 31.00M | 34.40M | 93.70M | 0.00 | 179.78M | 63.01M | 0.00 | 0.00 | -14.57M |
| Interest Expense | 35.80M | 38.03M | 1.80B | 1.85B | 1.73B | 849.69M | 963.52M | 969.01M | 1.21B | 969.70M | 1.45B | 1.04B | 1.01B | 556.20M | 426.20M | 321.54M | 116.46M | 170.48M | 133.33M | 99.56M |
| Depreciation & Amortization | 367.11M | 391.23M | 437.77M | 455.94M | 432.19M | 540.02M | 572.82M | 679.51M | 733.20M | 672.40M | 711.00M | 859.90M | 771.30M | 773.10M | 647.70M | 762.18M | 465.88M | 376.19M | 186.52M | 166.11M |
| EBITDA | 415.37M | 563.65M | 16.74B | 866.06M | 456.49M | 2.07B | 941.25M | 1.16B | 1.81B | 723.60M | 1.10B | -676.50M | -774.80M | 2.99B | 2.20B | 245.48M | 2.50B | 2.67B | 1.32B | 692.52M |
| EBITDA Ratio | 7.53% | -10.87% | -0.25% | 14.06% | 16.84% | -19.81% | 15.55% | 19.60% | 19.83% | 9.55% | -14.23% | -16.66% | -10.93% | 25.71% | 24.46% | 3.14% | 29.67% | 31.70% | 24.34% | 21.12% |
| Operating Income | 0.00 | -1.06B | -537.05M | 327.85M | 115.67M | -1.18B | 287.57M | -567.20M | -189.30M | -994.10M | -1.11B | -2.53B | -2.55B | 2.02B | 1.56B | -514.91M | 2.03B | 2.29B | 1.13B | 526.41M |
| Operating Income Ratio | 0.00% | -23.19% | -8.15% | 5.31% | 2.15% | -26.03% | 4.91% | -10.58% | -2.90% | -14.47% | -21.76% | -41.59% | -35.96% | 17.26% | 17.34% | -6.53% | 24.13% | 27.24% | 20.90% | 16.05% |
| Total Other Income/Expenses | 14.77M | 1.16B | 15.03B | -1.87B | -2.13B | 1.61B | -1.05B | -1.00B | -799.20M | -1.24B | 221.80M | -1.21B | -1.42B | -350.40M | -434.20M | -351.76M | -184.05M | -173.10M | -140.75M | -134.62M |
| Income Before Tax | 14.77M | 128.05M | 14.49B | -1.44B | -1.71B | 486.15M | -637.35M | -518.78M | -189.30M | -994.10M | -1.11B | -2.53B | -2.55B | 1.67B | 1.13B | -866.66M | 1.88B | 2.12B | 986.84M | 402.46M |
| Income Before Tax Ratio | 0.27% | 2.80% | 219.86% | -23.35% | -31.87% | 10.75% | -10.88% | -9.68% | -2.90% | -14.47% | -21.76% | -41.59% | -35.96% | 14.26% | 12.52% | -11.00% | 22.30% | 25.15% | 18.21% | 12.27% |
| Income Tax Expense | 29.82M | 465.50M | 3.71B | 19.57M | 166.40M | 77.07M | 98.58M | -109.80M | 19.20M | 30.80M | 16.80M | -187.60M | -541.90M | 218.90M | 403.60M | 206.74M | 586.21M | 642.11M | 394.38M | 129.54M |
| Net Income | -11.73M | -332.37M | 10.78B | -1.48B | -1.94B | 377.27M | -739.78M | -562.00M | -182.90M | -1.07B | -1.12B | -2.34B | -2.06B | 1.45B | 724.20M | -659.92M | 1.29B | 1.48B | 592.47M | 272.92M |
| Net Income Ratio | -0.21% | -7.27% | 163.57% | -23.91% | -36.16% | 8.34% | -12.62% | -10.48% | -2.80% | -15.50% | -21.99% | -38.50% | -28.96% | 12.39% | 8.04% | -8.37% | 15.33% | 17.53% | 10.93% | 8.32% |
| EPS | -0.19 | -5.43 | 176.05 | -24.11 | -31.72 | 6.16 | -12.08 | -9.18 | -2.99 | -17.39 | -18.31 | -38.25 | -33.58 | 22.98 | 12.24 | -9.89 | 19.51 | 23.84 | 9.57 | 3.91 |
| EPS Diluted | -0.19 | -5.43 | 176.05 | -24.11 | -31.72 | 6.16 | -12.08 | -9.18 | -2.99 | -17.39 | -18.31 | -38.25 | -33.58 | 22.98 | 11.46 | -9.26 | 18.25 | 21.85 | 9.36 | 3.91 |
| Weighted Avg Shares Out | 61.58M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 63.24M | 66.78M | 66.69M | 66.12M | 60.95M | 57.08M | 57.08M |
| Weighted Avg Shares Out (Dil) | 61.58M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 61.25M | 63.24M | 71.32M | 71.24M | 70.66M | 66.50M | 59.29M | 57.08M |
Source: https://incomestatements.info
Category: Stock Reports